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ABSTRACT
Introduction: Up to one third of colorectal cancers show familial clustering and 5% are hereditary 
single-gene disorders. Hereditary non-polyposis colorectal cancer comprises DNA mismatch repair- 
deficient and -proficient subsets, represented by Lynch syndrome (LS) and familial colorectal cancer 
type X (FCCTX), respectively. Accurate knowledge of molecular etiology and genotype-phenotype 
correlations are critical for tailored cancer prevention and treatment.
Areas covered: The authors highlight advances in the molecular dissection of hereditary non-polyposis 
colorectal cancer, based on recent literature retrieved from PubMed. Future possibilities for novel gene 
discoveries are discussed.
Expert commentary: LS is molecularly well established, but new information is accumulating of the 
associated clinical and tumor phenotypes. FCCTX remains poorly defined, but several promising 
candidate genes have been discovered and share some preferential biological pathways. Multi-level 
characterization of specimens from large patient cohorts representing multiple populations, combined 
with proper bioinformatic and functional analyses, will be necessary to resolve the outstanding 
questions.
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1. Introduction: lynch syndrome
1.1. MLH1, MSH2, MSH6, and PMS2 mutations in lynch 
syndrome predisposition
Lynch syndrome (LS) is an autosomal dominant disorder 
caused by a defect in one of the DNA mismatch repair 
(MMR) genes MLH1, MSH2, MSH6, or PMS2 [1]. It represents 
the MMR-deficient subgroup of hereditary non-polyposis col-
orectal cancer (HNPCC) (please see section 2.1. below for the 
evolution of nomenclature). LS is one the most prevalent 
hereditary cancer syndromes in man, with 1:226 individuals 
as the highest reported population frequency to date [2]. LS 
accounts for 1–3% of unselected colorectal or endometrial 
carcinomas and ~15% of those with high-degree microsatellite 
instability (MSI) or absent MMR protein in tumor tissues [3].
LS-associated MMR genes are conserved in evolution 
(Table 1). A specific clinical phenotype or syndrome exists for 
all known human MMR genes, except for MSH4 and MSH5 
whose protein products are necessary for meiotic (and possi-
bly mitotic) recombination but do not participate in MMR [4], 
and PMS1 whose product forms a complex with MLH1 but no 
specific function has been identified for this complex (hMutLβ) 
to date [5]. Of the over 3000 unique germline sequence var-
iants of the four LS-associated MMR genes deposited in the 
InSiGHT locus-specific database, the relative shares are 40% for 
MLH1, 34% for MSH2, 18% for MSH6, and 8% for PMS2 [6]. 
MLH1 and MSH2 proteins are obligatory components in all 
types of heterodimers that the MMR proteins form with each 
other [5] which explains the predominant roles of MLH1 and 
MSH2 in LS predisposition. MSH6 is functionally redundant 
with MSH3 when these proteins form a complex (hMutSα 
and hMutSβ, respectively) with MSH2 for mismatch recogni-
tion. A MutL homolog is needed to couple mismatch recogni-
tion to the downstream events. In humans, the prevalent MutL 
homolog is a heterodimer of MLH1 and PMS2 (hMutLα), but 
MLH1 can also heterodimerize with MLH3 (hMutLγ) which is 
able to partially compensate for the lack of hMutLα in 
MMR [5].
In comparison with the average population, heterozygous 
carriers of MMR gene mutations have significantly increased 
risks of cancers of the colon and rectum, endometrium, ovary, 
kidney, and urinary tract, upper gastrointestinal tract, and 
certain other organs. Compared to previous retrospective 
and family-based studies, recent prospective investigations 
have arrived at generally lower risk estimates for cancers 
occurring in LS, after stratification of cancer risk by the 
affected MMR gene, age, and gender [7]. Penetrance and 
expression patterns strongly depend on the MMR gene 
involved so that germline mutations of MLH1 and MSH2 
have the highest and PMS2 the lowest penetrance, whereas 
MSH6 mutations underlie a sex-limited trait with a high risk of 
gynecological cancers in females [7]. Evolutionary pathways to 
cancer may vary (for example, colorectal cancer development 
in LS may or may not involve a visible polyp precursor), and 
differential somatic involvement of key cancer-relevant genes 
(such as APC and CTNNB1) may in part explain differences in 
(colon) tumor development and penetrance between the four 
LS-associated MMR genes [8,9].
Germline mutations in MMR genes are detectable in up to 
88% of families strongly suspected of having LS based on the 
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fulfillment of the Amsterdam criteria and presence of MSI in 
tumors [10,11]. Mutation frequencies in smaller or atypical 
families and families not pre-screened by MSI or immunohis-
tochemical analyses vary between 10% and 40% depending 
on the method of ascertainment [10,12]. The detection rate of 
MMR gene mutations in families harboring such mutations is 
anticipated to increase when deep sequencing by targeted 
gene panels, or even whole exomes or genomes, will gradually 
replace single gene-based approaches. On the other hand, 
these new sensitive and comprehensive sequencing methods 
are likely to detect increasing numbers of variants of uncertain 
significance (VUS) which cannot be directly translated to clin-
ical management [13,14]. Furthermore, panels that include 
predisposition genes for multiple cancer syndromes may 
broaden genotype-phenotype associations within the syn-
dromes. For example, a retrospective review of clinical his-
tories in patients who underwent multigene panel testing 
and were diagnosed with a germline mutation in one of the 
MMR genes, showed the predominance of MSH6 and PMS2 
over MSH2 and MLH1 mutations and linked a hereditary breast 
and ovarian cancer phenotype to MSH6 and PMS2 muta-
tions [14].
1.2. Constitutional epimutations in LS predisposition
In cases suspected of having LS but with no identifiable cod-
ing region mutations, constitutional epimutations are worthy 
of consideration. Constitutional epimutation refers to consti-
tutional hypermethylation at the promoter of one allele of a 
given (non-imprinted) gene leading to silencing of expression 
from that allele in all main somatic tissues. Epimutation can be 
induced by a genetic alteration (usually located in cis), in 
which case epimutation is secondary, whereas epimutation 
arising in the absence of any detectable genetic change is 
considered primary. For MLH1, primary and secondary epimu-
tations are known, whereas constitutional epimutations of 
MSH2 are secondary to deletions of the 3ʹ end of the EPCAM 
gene (Table 2). After removal of stop codon, transcription of 
EPCAM reads into the adjacent, structurally normal MSH2 gene 
inducing its promoter methylation [15]. Owing to the capabil-
ity of MSH2 silencing, EPCAM is considered as a LS predisposi-
tion gene in addition to the four LS-associated MMR genes.
Depending on the method of ascertainment, constitutional 
epimutations of MLH1 (primary or secondary) may explain 1– 
10% of LS-suspected cases without traditional genetic muta-
tions and with absent MLH1 expression in tumor tissue [20– 
23]. Distinction of primary epimutations of MLH1 from those 
that are secondary to genetic changes is challenging, since a 
comprehensive screening of the MLH1 region [24], and in fact, 
the entire genome, would be required for a reliable exclusion 
of a possible inducing alteration. Constitutional epimutations 
are rare among unselected colorectal cancer patients: in a 
study on one such series from Spain, no MLH1 constitutional 
epimutations were detected [25]. On the other hand, low-level 
methylation may be missed by standard techniques: a sensi-
tive method used by Damaso et al. [26] was able to detect 
constitutional MLH1 methylation at 1% level in 1/18 (6%) 
patients with MLH1 hypermethylated colorectal tumors. The 
share of EPCAM deletion-associated constitutional epimuta-
tions of MSH2 among Lynch suspected families without con-
ventional germline mutations and with absent MSH2 protein 
in tumor tissues varies between 0% and 40% depending on 
possible founder effects [15,23]. Apart from MLH1 and MSH2, 
Article highlights
● Hereditary non-polyposis colorectal cancer refers to cancer predispo-
sition caused by single genes affected with high-penetrance muta-
tions. Transmission is usually autosomal dominant. While colorectal 
tumorigenesis may involve polyp precursors, no significant polyposis 
is present.
● DNA mismatch repair deficiency vs. proficiency divides hereditary 
non-polyposis colorectal cancer into two genetically and clinically 
distinct categories, Lynch syndrome and familial colorectal cancer 
type X, respectively.
● Germline mutations in MLH1, MSH2, MSH6, PMS2, and EPCAM cause 
predisposition to Lynch syndrome. Over 3,000 different germline 
mutations are known.
● Following somatic inactivation of the wild-type allele, tumor tissues 
from Lynch syndrome patients show absent mismatch repair protein 
(s) and high-degree microsatellite instability. Defective mismatch 
repair results in increased numbers of somatic mutations in other 
genes (hypermutability).
● Clinical phenotype of Lynch syndrome depends on the predisposing 
gene and typically involves colorectal and extracolonic cancers. 
Constitutional homozygosity for mismatch repair gene mutations 
gives rise to distinct clinical features and frequent polyposis.
● No established major predisposition genes are known for familial 
colorectal cancer type X, but several candidate genes have been 
proposed, each affected in a few families or a single family. The 
genes may participate in protein glycosylation (GALNT12), ribosome 
biosynthesis (RPS20 and BRF1), DNA repair (FAN1), or various other 
biological pathways.
● Tumors from patients with familial colorectal cancer type X are 
mismatch repair-proficient and microsatellite-stable. Somatic muta-
tional signatures may provide clues to the predisposing genes 
involved.
● While the low numbers of mutation carriers make assessments of 
tumor spectra and other clinical features unreliable, site-specific 
colorectal cancer diagnosed at somewhat later ages compared to 
Lynch syndrome appears true for most families with colorectal cancer 
type X.
● Genome-wide profiling of constitutional and tumor tissues, combined 
with functional investigations, are likely to define genotype-pheno-
type correlations in the existing syndromes and identify novel high- 
penetrance susceptibility genes for familial colorectal cancer type X.
Table 1. LS-associated MMR genes in evolution and phenotypes resulting from 
germline mutations.
E. 
coli S. cerevisiae H. sapiens
Phenotype resulting from germline 
mutation
MutS Msh2 MSH2 LS (monoallelic), CMMRD (biallelic)
Msh6 MSH6 LS (monoallelic), CMMRD (biallelic)
Msh3 MSH3 Attenuated adenomatous polyposis/ 
CMMRD (biallelic)
Msh1 Not identified N/A
Msh4 MSH4 No LS-associated mutations known
Msh5 MSH5 No LS-associated mutations known
MutL Mlh1 MLH1 LS (monoallelic), CMMRD (biallelic)
Pms1 PMS2 LS with reduced penetrance 
(monoallelic), CMMRD (biallelic)
Mlh2 PMS1 No LS-associated mutations known
Mlh3 MLH3 LS? (monoallelic), adenomatous 
polyposis (biallelic)
MutH Not identified Not identified N/A
N/A, not applicable 
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no constitutional epimutations have been reported for the 
remaining MMR genes [27].
The clinical phenotype of constitutional epimutation car-
riers is indistinguishable from that of conventional LS muta-
tion carriers. For occasional carriers of MLH1 epimutation, 
atypical phenotypes, such as colonic polyposis, have been 
reported [28]. EPCAM deletion carriers have a high risk of 
colorectal cancer, whereas only deletions extending close to 
the MSH2 promoter are associated with increased endometrial 
cancer risk [29]. In analogy to conventional LS mutations, 
tumor tissues show MSI and absent MMR protein(s) following 
inactivation of the wild-type allele by a genetic or epigenetic 
mechanism [15,20,30–32].
Since epigenetic changes are erased on passage through 
the germline, they are not regularly transmitted from parent 
to child. Therefore, primary constitutional epimutations segre-
gate in a non-Mendelian fashion and are seldom associated 
with any remarkable family history of cancer, which makes a 
clear distinction relative to LS arising from genetic mutations. 
Mosaic epigenetic inheritance and reversion of the methylated 
allele to normal active state have been observed in families of 
primary epimutation carriers, and occasionally apparent herit-
ability is seen [21,33–35]. In contrast, secondary epimutations 
of MLH1 or MSH2 give rise to classical LS families and co- 
segregate with their cis-acting genetic changes as dominant 
Mendelian traits [15,24]. However, there is evidence that the 
basic mechanism of transmission differs from that of a genetic 
mutation: a secondary epimutation of MLH1 was found to 
undergo a complete but transient reversion in the germline, 
being erased in spermatozoa but reinstated in somatic cells of 
the next generation [36].
1.3. Lynch-like ‘syndrome’ – a LS mimic
MLH1 promoter methylation as an acquired (somatic) alteration 
is by far the most frequent cause of MMR deficiency in various 
carcinomas, attributable to 10–20% of all colorectal carcinomas 
and 30% of endometrial carcinomas [37,38]. Germline mutations 
of MMR genes indicative of LS are detected in 1–3% of 
unselected colorectal or endometrial carcinomas [3]. MMR-defi-
cient cancers not explained by either of the two mechanisms 
mentioned above represent Lynch-like syndrome (LLS). The 
share of all colorectal carcinomas that LLS is responsible for (2– 
3%) [37,39] is comparable to LS. Two somatic mutations of the 
MMR genes MLH1, MSH2, MSH6, or PMS2 are detectable in more 
than half of LLS tumors [2,37,40–42]; this subset of LLS tumors is 
referred to as double somatic cases.
A higher average age at onset compared to LS is a feature of 
LLS [37,43], but on the level of an individual patient, LLS cannot 
be reliably distinguished from LS on clinical or histopathological 
grounds [39,44]. Some LLS cases are young and a (minor) pro-
portion shows a positive family history [39,45], raising the possi-
bility of a hereditary entity (even in the proven double somatic 
subset). Rare likely pathogenic germline variants in repair genes 
and other genes that maintain genome integrity were detected 
in LLS by Vargas-Parra et al. [46] (BUB1, SETD2, FAN1, and hetero-
zygous variant of MUTYH) and Xicola et al. [47] (WRN, MCPH1, 
BARD1, and REV3 L). Additionally, tumors from variant carriers 
exhibited a mutational signature different from that seen in 
tumors from LLS patients without such variants, suggesting a 
possibly distinct etiology in the former group [47]. On the other 
hand, Pico et al. [45] found that LLS patients had homogeneous 
clinical and pathology characteristics regardless of family history 
of colorectal cancer, arguing against the existence of ‘sporadic’ 
and ‘hereditary’ subgroups within LLS. Future studies are neces-
sary to resolve this question.
1.4. Homozygosity for MMR gene mutations – a shift from 
non-polypotic colorectal cancer to polyposis
To date, 100–200 patients have been reported to have 
homozygous or compound heterozygous germline mutations 
in any one of the four LS-associated MMR genes. These 
patients represent the constitutional mismatch repair defi-
ciency (CMMRD) syndrome [48–50]. The syndrome is charac-
terized by childhood cancers such as hematological 
malignancies and brain tumors, signs of neurofibromatosis 
type 1 (café-au-lait spots), and early-onset colorectal cancer. 
The distinct tumor spectrum may reflect sensitivity of neural 
and hematological progenitor cells to deficient MMR through 
Table 2. Constitutional epimutations of MLH1 and MSH2 in LS predisposition.
a MLH1 MSH2
Type of epimutation Primary or secondary Secondary
Published gene defects behind Genomic deletion of MLH1 exons 1–2 [20] Deletions of EPCAM removing stop codon [15,16,29]
secondary epimutation Genomic deletion of MLH1 exon 1 [17]
Duplication of MLH1 and flanking regions [18]
Duplication of MLH1 exons 1–6 [24]
c.-167delA in MLH1 promoter [24]
c.-63_-58delins18 in MLH1 promoter [19]
c.-27 C > A in MLH1 promoter [36]
c.27 G > A (synonymous) in MLH1 exon 1 [8,24]
AluYc insertion in 3ʹ end of MLH1 exon 1 [24]
c.116 + 106 G > A in MLH1 intron 1 [24]
Pattern of transmission Variable, from apparent lack of heritability Autosomal dominant
(primary epimutation) to autosomal
dominant (secondary epimutation)
Share of LSa 1–10% 10–40%
aEstimated from Lynch-suspected cases with MMR-deficient tumors and negative screens for conventional germline mutations in MMR genes. 
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mutational inactivation of certain key genes such as NF1 [51]. 
Since both alleles of the involved MMR gene are mutant in the 
germline, the respective protein is absent in normal tissues in 
addition to tumors. On the other hand, microsatellite length 
variants induced by defective MMR occur at such low levels in 
nonneoplastic tissues that their detection requires sensitive 
techniques [50,52,53].
The predominant genes underlying CMMRD are PMS2 and 
MSH6 [50]. When heterozygous, PMS2 mutations cause predis-
position to LS with low penetrance [7,54], whereas homozyg-
osity or compound heterozygosity for PMS2 mutations gives 
rise to CMMRD with full penetrance [50]. Adenomatous poly-
posis ranging from a few polyps to familial adenomatous 
polyposis-like phenotype is a regular feature of CMMRD 
[55,56]. In addition to CMMRD due to biallelic germline muta-
tions of the four LS-associated MMR genes (especially PMS2), 
polyposis is the leading phenotypic feature in the rare patients 
with biallelic germline mutations of MSH3 [57] and MLH3 [58]. 
In heterozygous states, MSH3 mutations are not known to be 
associated with any apparent disease phenotype [57], and 
MLH3 mutations may act as low-penetrance susceptibility fac-
tors for colorectal cancer [59,60]. In CMMRD, germline inacti-
vation of both alleles of the MMR gene in question, together 
with somatic polymerase exonuclease domain mutations, was 
shown to result in an ‘ultra-hypermutated’ tumor phenotype 
(over 100 mutations/Mb) in brain tumors, whereas gastroin-
testinal polyps revealed no increased mutational load com-
pared with adult polyps [61]. Moreover, no microsatellite 
instability (at dinucleotide or trinucleotide repeats) was 
observed in a polyp from a homozygous carrier of a nonsense 
mutation in PSM2 [62]. Tumor tissues from biallelic MSH3 
mutation carriers showed a distinct form of microsatellite 
instability called EMAST (Elevated Microsatellite Alterations at 
Selected Tetranucleotide Repeats) [57]. No instability at any 
type of microsatellite repeats was found in polyps or cancer 
tissues from biallelic MLH3 mutation carriers [58]. Absent or 
low-degree MSI may reflect partial redundancy between the 
different hMutS and hMutL dimers (see above).
At present, no definitive explanation is available for polyp 
predisposition in biallelic carriers of MMR gene mutations. At 
least one somatic APC mutation was detected in each of three 
PMS2-associated polyps examined by Siraj et al. [62], implying that 
inactivation of APC, a gatekeeper of cellular proliferation, is impor-
tant for tumor development. In MSH3-associated tumors, the 
observed inflammatory infiltration and the spectrum of somatic 
APC mutations (small deletions at repeat sequences) pointed to 
the significance of MMR deficiency in tumorigenesis [57]. Finally, in 
MLH3-associated tumors, multiple loci revealed allelic imbalance, 
suggesting the possible involvement of chromosomal segregation 
or recombination-related mechanisms [58].
2. Familial colorectal cancer type x
2.1. Division of hereditary non-polyposis colorectal 
cancer into two main entities
MMR-proficient families meeting the Amsterdam criteria [63,64] 
are referred to as familial colorectal cancer ‘type X’ (FCCTX); ‘type 
X’ implies that the genetic basis is largely unknown [65,66]. Prior 
to the discovery of the LS-associated MMR genes in the 1990 s, 
the Amsterdam Criteria were used to identify families with a 
presumably inherited form of colorectal carcinoma termed 
HNPCC. Molecular analyses have revealed that LS accounts for 
approximately half of such families, whereas, in the remaining 
families (FCCTX), no MSI or absent MMR protein in tumor tissue 
or germline MMR gene defect is detectable [65]. FCCTX families 
show site-specific (mainly distal) colorectal cancer, as opposed to 
colonic (mainly proximal) and extracolonic cancers seen in LS 
(Table 3). The mean age at cancer onset is around 55 years in 
FCCTX vs. 45 years in LS [67].
Apart from MMR status, the epigenomic pattern differs 
between FCCTX and LS (Table 3). Colorectal carcinomas from 
FCCTX families display a remarkably low LINE-1 methylation, 
which is a surrogate marker of global hypomethylation [68]. In 
contrast, extensive LINE-1 hypomethylation is not characteris-
tic of LS-colorectal cancers; a subset associated with a poor 
prognosis may constitute an exception [69]. In FCCTX patients, 
low LINE-1 methylation is a feature of normal mucosae, too 
[70] and may, therefore, represent a field defect or a constitu-
tional alteration. The mechanistic basis of FCCTX-associated 
hypomethylation is unknown.
2.2. Candidate susceptibility genes for FCCTX
Genome-wide sequencing and other approaches have resulted 
in the discovery of novel candidate genes for FCCTX. Selected 
candidate genes with functional proof available are listed in 
Table 4. Each gene appears to be involved in only a small fraction 
of families and no major FCCTX susceptibility genes, analogous 
to MMR genes in LS, have been identified to date. The genes 
cluster into some preferential biological pathways to be 
described in detail below (Table 4, Figure 1).
2.2.1. Protein glycosylation
2.2.1.1. GALNT12. Genetic linkage studies have provided evi-
dence of the existence of a colorectal cancer susceptibility gene 
on chromosome 9q22 but the responsible genes remain elusive 
[71–73]. GALNT12 is one of the genes located in that chromoso-
mal region and codes for the N-acetylgalactosaminyltransferase 
12 enzyme involved in O-linked glycosylation of mucin-type 
Table 3. Two main subgroups of hereditary non-polyposis colorectal cancer 
(HNPCC).
LS FCCTX
Share of HNPCC ~Half ~Half
Age at cancer onset 45 years 50–60 years
Tumor spectrum Colon cancer & 
extracolonic cancers
Site-specific colorectal 
cancer
Precursor lesion of 
colorectal cancer
Adenomatous polyp Adenomatous polyp
Transmission pattern Autosomal dominant Autosomal dominant
Predisposing genes MLH1, MSH2, MSH6, 
PMS2, EPCAM
Mostly unknown, candidate 
genes exista
Tumor characteristics MMR-deficient and 
hypermutant,
MMR-proficient, typically 
non-hypermutant,
CIMP may be present global hypomethylation 
present
aPlease see Table 4. 
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glycans. GALNT12 was originally identified as a possible colon 
cancer susceptibility gene by a candidate gene approach, based 
on the knowledge of aberrant glycosylation as a hallmark of 
colon cancers and the high level of expression of GALNT12 in 
normal colon [74]. Germline mutations of mainly missense type 
and leading to lost or reduced enzymatic activity of GALNT12 
were identified in 2–3% of colorectal cancer patients with vari-
able family histories, ranging from apparently sporadic cases to 
families referred to a cancer genetics clinic (Table 4; refs [74– 
76].). No GALNT12 germline mutations were detected in 103 
families meeting the stringent Amsterdam criteria [77]. The 
results argue against GALNT12 as a major high-penetrance sus-
ceptibility gene for FCCTX and provide evidence to support a 
role for GALNT12 as a moderate penetrance gene for colorectal 
cancer.
2.2.2. Ribosome biosynthesis
2.2.2.1. RPS20. Genome-wide linkage analysis in a multi- 
generation Finnish FCCTX family fulfilling the Amsterdam cri-
teria identified an area of linkage around the centromeric 
region of chromosome 8, and the RPS20 gene from that region 
(8q12.1) was subsequently found to be mutant in four colon 
cancer-affected siblings by exome sequencing (Table 4; ref. 
[78]). The mutation (c.147dupA) shared by the siblings was 
predicted to cause a frameshift and premature truncation. 
RPS20 encodes a component of the 40 S small ribosomal 
subunit. RNA analyses revealed a defect in the late steps of 
ribosome biogenesis affecting the formation of mature 18 S 
rRNA [78]. Later investigations identified germline mutations 
(truncating or missense) in three additional probands, two of 
which represented familial colon cancer cases of European 
ancestry belonging to the UK National Study of Colorectal 
Cancer Genetics [79] while the third one represented an 
Amsterdam criteria-positive MMR-proficient family from Utah 
[80]. Studies on colorectal cancers from RPS20-associated 
families [78,80] revealed no loss of the wild-type allele, con-
sistent with observations from zebrafish showing that riboso-
mal protein genes act as haploinsufficient suppressors of 
tumorigenesis [81].
Ribosome dysgenesis is connected to cancer in many ways, 
often involving p53 activation [82,83]. Western blot analysis of 
lymphoblastoid cells from RPS20 mutation carriers showed 
increased expression of p53 protein [78]. The same applies 
to germline mutation carriers of several other ribosomal pro-
teins, such as RPL26 [84]; unlike RPS20 mutations, heterozy-
gous germline mutations of other ribosomal protein genes are 
not associated with FCCTX but Diamond-Blackfan anemia 
(DBA), a rare bone marrow failure syndrome with red cell 
aplasia and congenital anomalies [83]. It is unknown why 
germline mutations of RPS20 underlie FCCTX while mutations 
of other ribosomal protein genes cause DBA. Some clinical 
overlap does exist: no significant anemia appears to accom-
pany RPS20 mutation, but mutations of DBA-associated ribo-
somal proteins cause significantly increased risk of colon 
cancer [85]. It is possible that different ribosomal proteins 
are rate-limiting in different cells, that different types of cells 
possess different sensitivity to p53 activation, or that p53 
pathway activation has different downstream effects in differ-
ent cells [83,86,87], thereby explaining tissue-specific manifes-
tations of mutant ribosomal protein genes.
2.2.2.2. BRF1. An exome sequencing study on three colon 
cancer affected relatives from an Amsterdam-positive FCCTX 
family from Spain identified a shared heterozygous splice site 
alteration (c.1459 + 2 T > C) that led to the skipping of exon 13 
of BRF1 (Table 4; ref. [88]). The protein product of BRF1 is part 
Figure 1. Pathways affected and interactions between genes involved in FCCTX predisposition. Generalized pathways for the FCCTX-associated genes were 
constructed according to the WikiPathways database and are indicated with colored circles. Only pathways with at least two affected genes were considered. 
Gene interactions with at least medium confidence according to the STRING database are indicated with black lines.
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of the TFIIB complex that initiates transcription by the RNA Pol 
III. Among other RNAs, RNA Pol III synthesizes 5 S ribosomal 
RNA, a limiting molecule required for the formation of the 
large 60 S ribosomal subunit [89]. A validation series of 502 
individuals with familial or early-onset colorectal cancer 
sequenced for the coding region and exon-intron boundaries 
of BRF1 revealed 10 independent families with rare heterozy-
gous germline mutations that affected protein expression 
and/or function of BRF1 [88]. Thus, BRF1 was mutant in a 
total of 2% (11/503) of all cases investigated, most of which 
met at least the revised Bethesda criteria [90] for hereditary 
non-polyposis colorectal cancer. In analogy to RPS20, color-
ectal tumors from BRF1-associated families showed no loss of 
the wild-type allele, supporting haploinsufficiency [88]. Taken 
together, cosegregation and functional evidence derived from 
several families having mutant RPS20 or BRF1 with converging 
functions, link ribosomal biosynthesis to colorectal cancer pre-
disposition, and RPS20 and BRF1 can be considered as high- 
penetrance susceptibility genes for FCCTX.
2.2.3. DNA repair and damage response
2.2.3.1. FAN1. Sequencing of the exomes of three colon 
cancer affected members from an Amsterdam-positive 
FCCTX family from Spain led to the discovery of a non-
sense mutation (c.141 C > A, p.C47*) in FAN1 which was 
shared by all affected family members and was absent in 
control individuals (Table 4; ref. [91]). FAN1 encodes 
FANCD2/FANCI-associated nuclease 1 involved in inter-
strand cross-link repair. Lymphoblastoid cells from a het-
erozygous mutation carrier showed increased sensitivity to 
mitomycin C which is characteristic of defects in Fanconi 
anemia-related genes and indicates impaired interstrand 
cross-link repair [91]. Homozygous FAN1 germline muta-
tions underlie karyomegalic interstitial nephritis, where 
chronic kidney failure is a predominating feature and pos-
sible cancer-associations are unknown due to the rarity of 
the syndrome [92]. A subsequent screen of 176 MMR-pro-
ficient Amsterdam-positive families identified 4 additional 
families with FAN1 germline mutations co-segregating with 
colorectal cancer in the families and having low mutant 
allele frequencies (<0.1%) in the control individuals [91]. 
Thus, FAN1 germline mutations accounted for a total of 5/ 
177 (3%) of Spanish FCCTX families. Colorectal tumors from 
FAN1 mutation carriers showed no evidence of somatic 
second hits, suggesting haploinsufficiency. The overall 
somatic mutational load in tumor tissue was in the non- 
hypermutant range [91].
Interpretations of the role of FAN1 mutations in FCCTX 
susceptibility are complicated by the fact that some popula-
tion-based control series, too, have been found to show dis-
ruptive FAN1 germline variants with frequencies less than 1% 
[79,91]. Analysis of the exomes of 863 familial colorectal can-
cer cases and 1604 controls from the UK National Study of 
Colorectal Cancer Genetics detected no significant increase of 
(likely) damaging FAN1 variants in cases (15/863, 1.7%) vs. 
controls (17/1604, 1.1%, p = 0.19). Therefore, additional inves-
tigations seem necessary to settle the role of defective FAN1 in 
FCCTX predisposition.
2.2.3.2. WRN and ERCC6. Arora et al. [93] pursued the 
hypothesis that constitutional defects in double-strand break 
(DSB) repair may underlie familial colorectal carcinomas of an 
undefined genetic basis. In addition to colorectal cancer, 25 
patients studied by Arora et al. [93] had cancers of several 
other organs and some also had (mild) polyposis. Following the 
observation that peripheral blood cells from familial colorectal 
cancer patients vs. controls showed higher levels of DSB-asso-
ciated γ(phospho)-H2AX foci after treatment with DNA-dama-
ging agents, the patients were subjected to exome sequencing. 
Compared to controls, a significantly higher frequency of disrup-
tive variants in genes relevant to DSB repair, nucleotide excision 
repair (NER), or other repair mechanisms were found. These 
included the WRN (RecQ-helicase-like) gene involved in DSB 
and the ERCC6 (excision repair cross-complementation group 6) 
gene involved in transcription-coupled NER. The variants 
occurred in a heterozygous state in the colon cancer patients 
and their consequences were validated by functional experi-
ments. Homozygous null mutations in WRN are known to cause 
Werner’s syndrome, while homozygous ERCC6 mutations cause 
Cockayne’s syndrome; Werner syndrome is associated with 
increased risks of various tumors, including gastrointestinal can-
cers [94], whereas in Cockayne’ syndrome, cells die prematurely 
which may offer protection against cancer development [95].
2.2.3.3. POT1, POLE2, and MRE11. Chubb et al. [96] 
hypothesized that rare high-impact alleles might contribute 
to the ‘missing heritability’ of colorectal cancer and conducted 
an exome sequencing-based epidemiological investigation on 
the occurrence of such alleles in 1006 early-onset familial 
colorectal cancer cases vs. 1609 healthy controls from the UK 
population. Highly penetrant rare mutations were identified in 
16% of familial colorectal cancer cases. Excluding established 
colon cancer susceptibility genes (such as MMR genes and 
APC), POT1 (Protection of Telomeres 1), POLE2 (DNA 
Polymerase Epsilon 2, Accessory Subunit), and MRE11 (MRE11 
Homolog, Double-Strand Break Repair Nuclease) were identi-
fied as new candidate colon cancer susceptibility genes, by 
virtue of truncating germline mutations that were significantly 
more frequent in cases than controls. The protein product of 
POT1 is part of the shelterin complex required for telomere 
maintenance. Heterozygous germline mutations have been 
associated with an autosomal dominant cancer family syn-
drome with diverse malignancies, such as glioma, angiosar-
coma, and melanoma [97]. POLE2 is part of the accessory 
(non-catalytic) subunit of the polymerase epsilon enzyme 
complex. In a previous study, targeted sequencing of polymer-
ase genes resulted in the identification of rare POLE2 variants 
(one truncating and one missense) in two patients with color-
ectal polyposis [98]. The MRE11 protein is involved in DSB 
repair, homologous recombination, and telomere length main-
tenance. Heterozygous germline mutations of MRE11 may 
cause increased breast cancer risk [99], whereas homozygous 
mutations underlie ataxia-telangiectasia-like disorder [100].
2.2.3.4. FAF1. Exome sequencing on 40 FCCTX families iden-
tified a missense variant (c.1111 G > A, p.Asp371Asn) in the 
FAF1 (Fas-associated factor 1) gene in an Amsterdam-positive 
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family of Spanish origin [101]. The variant was present in all 
four affected family members tested, including three with 
colorectal cancer and one with advanced adenoma. Targeted 
sequencing of FAF1 was subsequently conducted on 473 addi-
tional families mostly fulfilling the revised Bethesda criteria, 
and another presumably pathogenic missense variant 
(c.254 G > C, p.Arg85Pro) was discovered. No co-segregation 
studies were possible in the latter family. The two missense 
variants together explained a 0.4% fraction (2/513) of color-
ectal cancer families investigated [101].
The FAF1 gene product is a tumor suppressor with diverse 
functions; among others, it is a negative regulator of NF-κB 
and Wnt signaling [101]. Fas-associated factor 1 also interacts 
with proteins involved, for example, in TFGβ signaling, Fas- 
mediated apoptosis, and ubiquitin-related functions [102]. The 
two missense variants detected by Bonjoch et al. [101] ren-
dered the resulting proteins unstable. When FAF1 was 
knocked out in DLD1 colorectal cancer cells, cellular prolifera-
tion increased, and the cells became resistant to programmed 
cell death. Transient expression of the missense variants in 
DLD1 knockout cells recapitulated the features mentioned 
above and revealed NF-κB and Wnt signaling activation, as 
judged from increased nuclear translocation of NF-κB, and 
impaired degradation and cytoplasmic accumulation of β- 
catenin, respectively. As pointed out by Bonjoch et al. [101], 
investigations of additional cohorts are necessary to confirm 
and further evaluate the significance of FAF1 as a FCCTX 
susceptibility gene.
2.2.4. Other pathways
2.2.4.1. SEMA4A. Combined linkage analysis and exome 
sequencing in an Amsterdam-positive FCCTX family from 
Austria identified a missense variant (c.232 G > A, p. 
Val78 Met) in SEMA4A as the only variant shared by all four 
colorectal cancer-affected members tested [103]. The gene is 
located on chromosome 1q22 and encodes semaphorine 4A, a 
membrane protein with various functions (e.g., in neuronal 
axon extension, immunomodulation, and cell proliferation). 
The Val78 Met mutation was associated with increased 
MAPK/Erk and PI3 K/Akt signaling. Semaphorins have been 
found to have pro- and anti-carcinogenic functions; here, the 
evidence as a whole suggested loss of function, which was 
further supported by homozygosity of the variant in colorectal 
tumor tissues from two heterozygous mutation carriers [103]. 
A targeted screen of 53 additional Amsterdam-positive FCCTX 
families from Austria, Germany, and the United States identi-
fied three further missense changes in SEMA4A; among these, 
the rare G484A and S326 F variants were predicted to be 
deleterious by in silico tools, whereas a case–control associa-
tion study suggested a significant enrichment of the single 
nucleotide polymorphism p.Pro682 Ser in FCCTX cases (6%) vs. 
controls (1%, p = 0.0008). However, an attempt to validate the 
proposed cancer-predisposing role of the recurrent G484A 
and P682S variants in an independent case–control study 
involving ~7,000 colorectal cancer cases and 10,000 controls 
from six European populations failed to do so [104]. 
Furthermore, the entire coding region of SEMA4A was 
sequenced in 158 FCCTX families, which resulted in the 
detection of protein changing variants in 16% of FCCTX 
families, compared with 14% of controls, suggesting no sig-
nificantly increased frequency of SEMA4A variants in FCCTX 
families [104]. In conclusion, additional investigations are 
needed to resolve the role of SEMA4A variants in FCCTX 
predisposition.
2.2.4.2. BMPR1A. Genome-wide linkage scan conducted on 
a large Amsterdam-positive FCCTX family from Finland 
resulted in the observation of tentative linkage on 10q23 
[105]. Sequencing of genes from the linked region revealed 
an in-frame germline mutation (c.264_266del, p.Glu88del) in 
exon 3 of BMPR1A which co-segregated with colon carcinoma 
and/or adenoma in the family [105]. The protein product of 
the BMPR1A gene is a type I bone morphogenetic protein 
receptor that belongs to a family of serine/threonine kinases. 
BMPR1A was subsequently sequenced in 17 additional Finnish 
families fulfilling the Amsterdam or Bethesda criteria and hav-
ing MMR-proficient tumors. The proband of an Amsterdam- 
positive family revealed a truncating splicing mutation; no 
other affected members from that family were available for 
co-segregation studies [105]. Neither of the two predisposing 
mutations, each occurring in one family [105], have been 
found in healthy reference populations.
Loss of function mutations of BMPR1A are known to under-
lie juvenile polyposis syndrome, characterized by hamartoma-
tous polyps and increased risk of gastrointestinal cancer [106]. 
Interplay between epithelial and stromal cells is believed to be 
important for the development of hamartomatous polyps, and 
loss of BMP signaling in the epithelial compartment alone may 
be insufficient [107,108]. For comparison, polyps from the two 
BMPR1A-linked FCCTX families described by Nieminen et al. 
[105] were of adenomatous histology and the highest com-
bined number of adenomatous and hyperplastic polyps per 
colonoscopy screen per person was 4; thus, the clinical picture 
was that of a non-polypotic colorectal cancer rather than 
polyposis. When bulk tumor tissues were investigated, the 
FCCTX-associated BMPR1A germline mutations were accompa-
nied by loss of heterozygosity in colorectal tumors: the spli-
cing mutation was associated with wild-type allele loss, 
whereas wild-type and mutant allele losses were equally com-
mon in tumors from the in-frame deletion carriers [105].
Additional phenotypes that BMPR1A germline mutations 
have been linked to include early-onset MMR-proficient col-
orectal cancer [109] and unexplained adenomatous polyposis 
[110]. The basis of the reported genotype-phenotype asso-
ciations is unknown. In the BMP signaling pathway, multiple 
ligand, receptor, and downstream effector combinations are 
possible and might allow for tissue or cell-specific responses. 
Furthermore, the seemingly different phenotypes may over-
lap. For example, Lieberman et al. [111] evaluated seven 
unrelated families sharing a genomic deletion of the entire 
coding region of BMPR1A and found extremely variable phe-
notypes despite the same predisposing mutation and the 
same genetic background (Bukharin Jewish ancestry). 
Importantly, adenomatous polyps predominated over juve-
nile polyps in the families [111]. Lastly, Evans et al. [112] 
conducted a targeted investigation on 22 unrelated FCCTX 
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families from Newfoundland to determine the frequency of 
BMPR1A germline mutations: no rare (mutant allele frequency 
< 1%) or novel variants were found. Therefore, studies on 
additional FCCTX families from different populations are war-
ranted to define the relationship between BMPR1A mutations 
and FCCTX.
3. Prospects to identify novel cancer-predisposing 
genes – challenges and promises
A single biological pathway, MMR, with the major players 
already known (Table 1) defines LS. The diagnosis of FCCTX 
on the other hand is based on the exclusion of LS and the 
demonstration of MMR-proficient tumors, until the responsible 
genes are identified. The available experience suggests that 
FCCTX is genetically heterogeneous and private genes and 
mutations may be the norm (Table 4). A burning question is 
how to best find the genes underlying colon cancer suscept-
ibility in the majority of FCCTX families that currently lack 
molecular definition.
3.1. Methodological considerations
Over the years, the discovery of new cancer predisposing 
genes has been based on three main strategies: candidate 
gene analysis, genetic linkage analysis, and most recently, 
genome-wide sequencing [113]. Large families with multiple 
cases of preferably early-onset colorectal cancer affecting sev-
eral generations would provide convincing evidence of a her-
editary nature of cancer predisposition and would obviously 
be ideal for searches for novel susceptibility genes. This set-
ting was utilized in previous linkage-based studies that led to 
the identification of many currently known colorectal cancer 
predisposition genes [114]. Genetic linkage analysis was also 
part of the strategies used to identify many of the FCCTX 
candidate genes listed in Table 4; however, genome-wide 
sequencing, usually of the whole exomes, is nowadays the 
main approach. While the available methods are constantly 
improving, some challenges remain and may guide searches 
for predisposing mutations that have possibly escaped detec-
tion. First, not all relevant regions of the genome may be 
covered. High-penetrance mutations are assumed to mainly 
reside in the coding portions of the genome, which is why 
exome sequencing is the preferred method. Exome sequen-
cing interrogates the exons and their immediate flanking 
regions (~ 2% of the human genome). However, some high- 
penetrance mutations may involve promoter regions, introns, 
or non-coding RNA. For example, mutations residing deep in 
the introns can activate sequences (pseudoexons) flanked by 
splice sites, which can result in the insertion of intronic 
sequences in the mature mRNA [115]. In such cases, whole- 
genome sequencing and RNA-sequencing would be required 
to catch the alteration [115]. Likewise, for the detection of 
constitutional epimutations, a combination of techniques 
(genetic and epigenetic) would be needed. Second, gaps 
may remain in data analysis. While single nucleotide variants 
(SNVs) are effectively detected by the available variant calling 
pipelines, the ability to accurately call insertion-deletion type 
changes (indels) remains imperfect [116]. The same applies to 
copy number variant (CNV) analysis, although CNV detection 
algorithms have been developed for whole genome, whole 
exome, and targeted deep sequencing data [117].
3.2. Data interpretation
Protein truncating variants, which predominate among known 
disease-causing germline mutations of cancer genes [118], are 
considered deleterious by nature. However, panel sequencing 
studies suggest that up to 40% of patients suspected to have 
a hereditary cancer syndrome may carry a variant of uncertain 
significance, VUS [119]. VUSes typically consist of single amino 
acid substitution (missense) changes which can be classified 
neither pathogenic nor harmless a priori. Even synonymous 
nucleotide changes (i.e., nucleotide substitutions which do not 
result in a coding change) can be pathogenic if they, for 
example, disrupt motifs for proper splicing [120]. Thus, if a 
novel candidate susceptibility gene is affected by non-truncat-
ing alterations alone, the cancer predisposing role of the gene 
may remain unknown in cases where confirmatory studies (e. 
g., co-segregation or functional investigations) are not possi-
ble. Occasionally, two or more variants (of the same gene or 
different genes) may co-exist and even co-segregate with 
disease phenotype in a single family, which could be compa-
tible with several alternative interpretations, including a true 
predisposing change coexisting with spurious variants, or a 
possibly multigenic basis of colon cancer susceptibility (see 
below).
3.3. Genotypic and phenotypic heterogeneity
A plausible reason why searches for new predisposition genes 
for FCCTX often fail is that FCCTX families do not have any 
pathognomonic features, either clinical (such as multiplicity 
and/or distinct histology of polyps that may aid the dissection 
of polyposis syndromes) or molecular (such as deficient MMR 
characteristic of LS), which could guide gene discovery efforts 
and distinguish true gene carriers from phenocopies (non- 
carriers). The possibility to investigate multiple (affected and 
unaffected) family members or utilize other hallmarks of her-
editary cancer besides family history (such as multiple tumors 
in a single individual or the combination of specific tumor 
types) can be important advantages. Genome-wide sequen-
cing studies have demonstrated that the inclusion of multiple 
affected family members who can reasonably be assumed to 
share the same high-penetrance susceptibility variant can sig-
nificantly reduce the number of candidate variants worth 
considering [78]. Tumor genotype and phenotype can likewise 
be informative, including the type of genomic instability and 
epigenomic pattern (Table 3) or mutational signature [121]. 
Since each mutational process leaves a specific imprint in the 
genome of a cell, somatic mutational signatures can offer 
clues to the predisposing genes involved. Diaz-Kay et al. 
[122] performed an integrated whole-exome analysis of germ-
line and tumor DNA to detect novel tumor suppressor genes 
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underlying familial colorectal cancer. They required that genes 
of interest should be altered in both normal and tumor DNA 
according to Knudson’s two-hit hypothesis. The strategy pin-
pointed DNA repair genes, including BRCA2, BLM, ERCC2, 
RECQL, REV3 L, and RIF1, and mutational signatures addition-
ally provided evidence of the existence of novel predisposition 
genes to be defined by further investigations [122].
3.4. Polygenic basis of colon cancer susceptibility
Rare high-penetrance variants in known susceptibility genes 
account for only ~5% of the total colorectal cancer burden 
[123]. Genome-wide association studies of common colorectal 
cancers have identified over 40 independent loci of low-pene-
trance risk variants frequent in the average population [124]. 
Each low-penetrance locus is estimated to increase colorectal 
cancer risk no more than up to 1.5-fold [123]. Although mostly 
residing outside coding regions, low-penetrance variants can 
influence the expression of genes from pathways associated 
with high-penetrance susceptibility genes (including, for exam-
ple, the TGFβ/BMP pathway [125]). Thus, epistatic (synergistic 
non-additive) interactions between two or more variants from 
different loci may account for some of the currently unex-
plained colorectal cancer susceptibility. Rare variants with mod-
erate effects are another worthwhile possibility in searches for 
novel colon cancer predisposition genes. This is because such 
variants are easily overlooked in family-based studies due to 
incomplete co-segregation, and the same could happen with 
genome-wide association studies because large sample sizes 
would be required to reach statistical significance [123].
4. Expert opinion
Hereditary non-polyposis colorectal cancer offers an illustra-
tive example of the remarkable progress that, along with 
technical developments, has taken place in understanding 
the genetic basis of human disorders in recent years. LS is 
well-defined in terms of predisposing genes, and genetic 
challenges that remain mainly concern optimal detection 
methods of predisposing variants and interpretation of clin-
ical significance of the variants. It is currently recommended 
that all new patients with colorectal or endometrial cancer 
should undergo systematic screening for LS, consisting of 
MSI and MMR protein tests on tumor tissue followed by 
further analyses (for MLH1 methylation and additionally, 
BRAF-V600E mutation for colorectal cancers), and ultimately, 
germline mutation testing when appropriate [126]. This ‘uni-
versal’ screening, combined with high-throughput sequen-
cing that is replacing gene-based methods in germline 
mutation detection, is likely to multiply the numbers of 
MMR gene variants that need to be annotated for patho-
genic significance. While various in silico tools [127] may be 
helpful for a preliminary assessment, there is an urgent need 
for functional tests robust enough that could unequivocally 
distinguish between normal and abnormal MMR gene func-
tion. LS carrier tests based on the effect of MMR protein 
dosage on MMR capability [128,129] are under development 
and/or already available for clinical diagnostics (DiagMMR®).
Increased knowledge of genotype-phenotype correlations 
in LS is expected to improve the possibilities of tailoring 
cancer prevention and treatment according to the predispos-
ing gene and variant [7,9] as well as the genetic, epigenetic, or 
immunological type of tumors [130,131]. Clinical trials con-
ducted to date have already established the responsiveness 
of LS and other hypermutant/MSI tumors to immune check-
point inhibitors, motivating the use of such drugs to treat 
metastatic/advanced disease [132]. At the same time, immu-
novaccination [133] and chemoprevention [134] represent 
promising new approaches for cancer prevention in LS.
Despite recent progress, the underlying genes remain to 
be identified for most cases of FCCTX. Even for those few 
families with plausible candidate genes discovered, the true 
predisposing nature of the genes and variants is typically 
awaiting further proof. The decreasing costs for genome- 
wide sequencing make investigations of larger patient 
cohorts affordable, thereby facilitating new gene discoveries 
on the one hand and providing accurate information of the 
molecular epidemiology of existing candidate genes and 
variants on the other hand. Experience from pan-cancer ana-
lysis of whole genomes shows that common and rare germ-
line variants influence the patterns of somatic mutations 
[135]; hence, mutational signatures of tumor tissues are 
becoming an integral part of future searches for FCCTX sus-
ceptibility genes. Moreover, a closer scrutiny of the non-cod-
ing genome (comprising 98% of the whole genome) is 
anticipated to pinpoint new genes and mechanisms that 
may underlie colon cancer susceptibility or modify the dis-
ease phenotype.
Based on available knowledge (Table 3), a modified cancer 
prevention protocol for FCCTX is currently recommended 
[136], consisting of colonoscopy once in every 5 years (vs. 
once in every 1–2 years in LS [126]) and starting from the 
age of 45 years (vs. 20–35 years in LS [126]). Cancer surveil-
lance in FCCTX focuses on colon cancer alone since extraco-
lonic cancers are considered rare. A reappraisal may be 
warranted since FCCTX families from a national (Danish) 
HNPCC register revealed an increased risk of five types of 
extracolonic cancers (cancers of the urinary tract, breast, sto-
mach, and pancreas, as well as ocular melanoma) compared to 
the average population [137]. In the study mentioned above 
[137], information of possible predisposing genes was not 
available, and FCCTX families were ascertained through the 
Amsterdam criteria and MMR-proficient tumors A better 
understanding of the individual nature of the susceptibility 
genes, their biological function and associated clinical features 
(including tumor spectra), is likely to refine protocols for can-
cer surveillance and enable targeted therapy for subsets of 
FCCTX in the future.
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